xtandi
astellas pharma europe b.v. - enzalutamide - prostata neoplasmer - endokrin terapi - xtandi is indicated for:the treatment of adult men with metastatic hormone-sensitive prostate cancer (mhspc) in combination with androgen deprivation therapy (see section 5. the treatment of adult men with high-risk non-metastatic castration-resistant prostate cancer (crpc) (see section 5. the treatment of adult men with metastatic crpc who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. the treatment of adult men with metastatic crpc whose disease has progressed on or after docetaxel therapy.
lipitor 40 mg
upjohn eesv - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 40 mg
lipitor 10 mg
upjohn eesv - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 10 mg
lipitor 20 mg
upjohn eesv - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 20 mg
lipitor 80 mg
upjohn eesv - atorvastatinkalsiumtrihydrat - tablett, filmdrasjert - 80 mg
targiniq 15 mg / 7.5 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 15 mg / 7.5 mg
targiniq 5 mg / 2.5 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 5 mg / 2.5 mg
targiniq 10 mg / 5 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 10 mg / 5 mg
targiniq 20 mg / 10 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 20 mg / 10 mg
targiniq 30 mg / 15 mg
mundipharma as - oksykodonhydroklorid / naloksonhydrokloriddihydrat - depottablett - 30 mg / 15 mg